The Real-Life Safety and Efficacy of Vardenafil (REALISE) Study: Results in Men from Europe and Overseas with Erectile Dysfunction and Cardiovascular or Metabolic Conditions

Journal of Sexual Medicine

Volumn 7, Issue 9, 2010, Pages 3161-3169

  van Ahlen, Hermann ^a   Zumbé, Jürgen ^b   Stauch, Kathrin ^c   Hanisch, Jens Ulrich ^c  

^a Andreas Bannowsky Ltd   (Germany)

^b KLINIKUM LEVERKUSEN   (Germany)

^c BAYER AG   (Germany)

Author keywords

Efficacy; Erectile dysfunction; International prospective Study; Post marketing surveillance study; Safety; Underlying conditions; Vardenafil

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; RENIN INHIBITOR; VARDENAFIL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASIA; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSULTATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; ERYTHEMA; EUROPE; FLUSHING; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; INTERVIEW; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NOSE CONGESTION; PACIFIC ISLANDS; PATIENT ATTITUDE; PATIENT SATISFACTION; PENIS ERECTION; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUESTIONNAIRE; SIDE EFFECT; SOUTH AND CENTRAL AMERICA; TREATMENT OUTCOME; UNITED STATES;

EID: 77956272479     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01921.x     Document Type: Article

References (35)

1. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993, 270:83-90. NIH Consensus Conference
2. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004, 20:607-17.
3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994, 151:54-61.
4. Aytaç IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999, 84:50-6.
5. Guay AT. ED2: Erectile dysfunction = endothelial dysfunction. Endocrinol Metab Clin North Am 2007, 36:453-63.
6. Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, McKinlay JB. Erectile dysfunction and coronary risk factors: Prospective results from the Massachusetts Male Aging Study. Prev Med 2000, 30:328-38.
7. Nehra A. Erectile dysfunction and cardiovascular disease: Efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc 2009, 84:139-48.
8. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: Results of the " Cologne Male Survey" Int J Impot Res 2000, 12:305-11.
9. Giuliano FA, Leriche A, Jaudinot EO, de Gendre AS. Prevalence of erectile dysfunction among 7,689 patients with diabetes or hypertension, or both. Urology 2004, 64:1196-201.
10. Inman BA, Sauver JL, Jacobson DJ, McGree ME, Nehra A, Lieber MM, Roger VL, Jacobsen SJ. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009, 84:108-13.
11. Martín Morales A, Mirone V, Dean J, Costa P. Vardenafil for the treatment of erectile dysfunction: An overview of the clinical evidence. Clin Interv Aging 2009, 4:463-72.
12. Brock G. Oral agents: First-line therapy for erectile dysfunction. Eur Urol Suppl 2002, 1:12-8.
13. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003, 26:777-83.
14. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H. Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002, 23:763-71.
15. Miner M, Billups KL. Erectile dysfunction and dyslipidemia: Relevance and role of phosphodiesterase type-5 inhibitors and statins. J Sex Med 2008, 5:1066-78.
16. Miner M, Gilderman L, Bailen J, Cook D, Dawson K, Stanislaus M, Beresford E, Barnes A. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med 2008, 5:1455-67.
17. Porst H, Young JM, Schmidt AC, Buvat J. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology 2003, 62:519-23. discussion 523-4
18. van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005, 2:856-64.
19. Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006, 3:883-91.
20. Zumbé J, Porst H, Sommer F, Grohmann W, Beneke M, Ulbrich E. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: Findings of the RESTORE study. Eur Urol 2008, 54:204-12.
21. Cheng E. Real-life safety and efficacy of vardenafil in the treatment of erectile dysfunction-results from 30,010 U.S. patients. J Sex Med 2007, 4:432-9.
22. Kamel A, Khaouli R, Sabha M, Al Mitwally K, Fouad W, Landen H. The real-life safety and efficacy of vardenafil: An international post-marketing surveillance study of 2,824 patients from the Middle East. Clin Drug Investig 2007, 27:339-46.
23. Tobing NL, Arsyad K, Manuputty D, Landen H, Syarif H. The real-life safety and efficacy of vardenafil: An international post-marketing study-Results from 1,171 Indonesian patients. Maj Kedokt Indon 2006, 56:468-73.
24. Trypens P, Depko A, Dadej R, Landen H. [The real-life safety and efficacy of vardenafil: An international post-marketing surveillance study-Results from 5,373 Polish patients]. Urol Pol 2006, 59:312-8.
25. van Ahlen H, Zumbé J, Landen H. POS-01.74: The real-life safety and efficacy of vardenafil (REALISE) study: Results from the pooled European and overseas study. Urology 2007, 70(1):212. suppl
26. van Ahlen H, Zumbé J, Stauch K, Landen H. The real-life safety and efficacy of vardenafil: An international post-marketing surveillance study-results from 29,358 German patients. J Int Med Res 2005, 33:337-48.
27. Levitra 5 mg, 10 mg, 20 mg film-coated tablets. http://www.ema.europa.eu/humandocs/PDFs/EPAR/levitra/emea-combined-h475en.pdf, Summary of Product Characteristics, June 22, 2009. Available at: (accessed July 6, 2010
28. Khoo EM, Tan HM, Low WY. Erectile dysfunction and comorbidities in aging men: An urban cross-sectional study in Malaysia. J Sex Med 2008, 5:2925-34.
29. Ma RC, So WY, Yang X, Yu LW, Kong AP, Ko GT, Chow CC, Cockram CS, Chan JC, Tong PC. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 2008, 51:2045-50.
30. Shabsigh R, Shah M, Sand M. Erectile dysfunction and men's health: Developing a comorbidity risk calculator. J Sex Med 2008, 5:1237-43.
31. Eardley I, Fisher W, Rosen RC, Niederberger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality study: The influence of diabetes on self-reported erectile function, attitudes and treatment-seeking patterns in men with erectile dysfunction. Int J Clin Pract 2007, 61:1446-53.
32. Kim CM, Kim YS, Sunwoo S, Cho B, Rho M, Yang YJ, Kim CH, Shin HC, Lee SY, Kim DH. Post-marketing surveillance study of the efficacy and safety of vardenafil among patients with erectile dysfunction in primary care. Int J Impot Res 2007, 19:393-7.
33. Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel TJ, Porst H. The efficacy and safety of flexible-dose vardenafil (Levitra®) in a broad population of European men. Eur Urol 2004, 45:634-41. discussion 641
34. Valiquette L, Young JM, Moncada I, Porst H, Vezina JG, Stancil BN, Edmunds K, Montorsi F. Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: A randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2005, 80:1291-7.
35. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: A systematic review. Drug Saf 2009, 32:19-31.